Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591287788> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2591287788 endingPage "332" @default.
- W2591287788 startingPage "332" @default.
- W2591287788 abstract "332 Background: Vinflunine (VFL) is the first agent to show a survival improvement for platinum-refractory patients (pts) with metastatic TCCU in a phase III clinical trial. After EMA approval in September 2009, ESMO (Bellmunt, 2011) and SOGUG (Castellano, 2012) guidelines recommend VFL as second-line therapy. Methods: This is a multicenter and retrospective study to describe the experience with VFL in Spain. Pts with histologically confirmed metastatic TCCU were treated with VFL (280-320mg/m2 every 3 weeks) until progression or unacceptable toxicity. Pts were evaluated according to institutional local follow-up program. Results: From April 2010 to June 2013, we registered 102 pts in fifteen Spanish centers. All patients are evaluable for safety and 98 for efficacy. Median age: 67years (range 45-83), ECOG 0/1/2 previous to VFL (pts%): 31/61/8. Bladder carcinoma was the primary disease site in 84 pts and 46 % of them received cisplatinum-based chemotherapy. Metastatic involvement was: lymph nodes 67.7%, lung 36.4%, bone 28.1%, and liver 21.6%. The median number of cycles of VFL was 4 (1-18). The objective response rate was 25.5% (CR in 2 pts and PR in 23 pts), stable disease in 42.9% and progressive disease in 31.6%. The median follow-up was 6.6 months (0.4 to 43): median progression-free survival 3.9 months (95% CI, 2.3 to 5.5), median time to progression 4.3 months (95% CI, 2.6 to 5.9) and median overall survival 10 months (95% CI, 7.3 to 12.8). At the time of the analysis, 79.4%pts had progressive disease after VFL and 64.7% died. Grade 3/4 adverse events included: nausea/vomiting 13.8% of pts, neutropenia 12.8%, constipation 5.9%, and abdominal pain 4.9%. No toxic death were reported. Conclusions: This retrospective analysis confirms the benefit of VFL in patients with TCCU after failure in a platinum-containing chemotherapy regimen. Results of the randomized trial are reproducible in Spanish Oncology Centers on a daily clinical practice and its toxicity profile results are acceptable and manageable." @default.
- W2591287788 created "2017-03-03" @default.
- W2591287788 creator A5001123101 @default.
- W2591287788 creator A5012542217 @default.
- W2591287788 creator A5013608612 @default.
- W2591287788 creator A5021248617 @default.
- W2591287788 creator A5023560654 @default.
- W2591287788 creator A5024147987 @default.
- W2591287788 creator A5026620381 @default.
- W2591287788 creator A5038614419 @default.
- W2591287788 creator A5057119670 @default.
- W2591287788 creator A5066375707 @default.
- W2591287788 creator A5066684629 @default.
- W2591287788 creator A5069897804 @default.
- W2591287788 date "2014-02-01" @default.
- W2591287788 modified "2023-10-18" @default.
- W2591287788 title "Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) after failure to one cisplatin-based systemic therapy in clinical practice." @default.
- W2591287788 doi "https://doi.org/10.1200/jco.2014.32.4_suppl.332" @default.
- W2591287788 hasPublicationYear "2014" @default.
- W2591287788 type Work @default.
- W2591287788 sameAs 2591287788 @default.
- W2591287788 citedByCount "0" @default.
- W2591287788 crossrefType "journal-article" @default.
- W2591287788 hasAuthorship W2591287788A5001123101 @default.
- W2591287788 hasAuthorship W2591287788A5012542217 @default.
- W2591287788 hasAuthorship W2591287788A5013608612 @default.
- W2591287788 hasAuthorship W2591287788A5021248617 @default.
- W2591287788 hasAuthorship W2591287788A5023560654 @default.
- W2591287788 hasAuthorship W2591287788A5024147987 @default.
- W2591287788 hasAuthorship W2591287788A5026620381 @default.
- W2591287788 hasAuthorship W2591287788A5038614419 @default.
- W2591287788 hasAuthorship W2591287788A5057119670 @default.
- W2591287788 hasAuthorship W2591287788A5066375707 @default.
- W2591287788 hasAuthorship W2591287788A5066684629 @default.
- W2591287788 hasAuthorship W2591287788A5069897804 @default.
- W2591287788 hasConcept C121608353 @default.
- W2591287788 hasConcept C126322002 @default.
- W2591287788 hasConcept C141071460 @default.
- W2591287788 hasConcept C143998085 @default.
- W2591287788 hasConcept C2776694085 @default.
- W2591287788 hasConcept C2778822529 @default.
- W2591287788 hasConcept C2780352672 @default.
- W2591287788 hasConcept C2780739268 @default.
- W2591287788 hasConcept C2911057145 @default.
- W2591287788 hasConcept C3019882237 @default.
- W2591287788 hasConcept C31760486 @default.
- W2591287788 hasConcept C71924100 @default.
- W2591287788 hasConcept C90924648 @default.
- W2591287788 hasConceptScore W2591287788C121608353 @default.
- W2591287788 hasConceptScore W2591287788C126322002 @default.
- W2591287788 hasConceptScore W2591287788C141071460 @default.
- W2591287788 hasConceptScore W2591287788C143998085 @default.
- W2591287788 hasConceptScore W2591287788C2776694085 @default.
- W2591287788 hasConceptScore W2591287788C2778822529 @default.
- W2591287788 hasConceptScore W2591287788C2780352672 @default.
- W2591287788 hasConceptScore W2591287788C2780739268 @default.
- W2591287788 hasConceptScore W2591287788C2911057145 @default.
- W2591287788 hasConceptScore W2591287788C3019882237 @default.
- W2591287788 hasConceptScore W2591287788C31760486 @default.
- W2591287788 hasConceptScore W2591287788C71924100 @default.
- W2591287788 hasConceptScore W2591287788C90924648 @default.
- W2591287788 hasIssue "4_suppl" @default.
- W2591287788 hasLocation W25912877881 @default.
- W2591287788 hasOpenAccess W2591287788 @default.
- W2591287788 hasPrimaryLocation W25912877881 @default.
- W2591287788 hasRelatedWork W1980050012 @default.
- W2591287788 hasRelatedWork W2038406412 @default.
- W2591287788 hasRelatedWork W2054340543 @default.
- W2591287788 hasRelatedWork W2103201965 @default.
- W2591287788 hasRelatedWork W2145118120 @default.
- W2591287788 hasRelatedWork W3009020698 @default.
- W2591287788 hasRelatedWork W4281558335 @default.
- W2591287788 hasRelatedWork W4296330869 @default.
- W2591287788 hasRelatedWork W4300968061 @default.
- W2591287788 hasRelatedWork W4324136739 @default.
- W2591287788 hasVolume "32" @default.
- W2591287788 isParatext "false" @default.
- W2591287788 isRetracted "false" @default.
- W2591287788 magId "2591287788" @default.
- W2591287788 workType "article" @default.